EOLS News and Press, Evolus Inc. From 06/08/23

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced it recently completed the one-millionth Jeuveau ® redemption through its Evolus Rewards™ patient loyalty program. “We designed Evolus ...

2023-05-09 22:53:01 ET Evolus, Inc. (EOLS) Q1 2023 Earnings Conference Call May 09, 2023 04:30 PM ET Company Participants David Erickson - VP, IR David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO ...

2023-05-09 16:08:18 ET Evolus press release ( NASDAQ: EOLS ): Q1 GAAP EPS of -$0.26 misses by $0.01 . Revenue of $41.7M (+23.0% Y/Y) beats by $1.18M . Evolus continues to expect total net revenues for the full year 2023 to be between $180 million and $190 milli...

Q1 2023 Net Revenue of $41.7 Million, Up 23% from Q1 2022 Reaffirms Full-Year 2023 Net Revenue Guidance of $180 to $190 Million Raises 2028 Revenue Outlook from $500 Million to $700 Million Driven by Addition of Evolysse™ Dermal Filler Line Representing a 29% CAGR F...

Portfolio of 5 Fillers in Late-Stage Development; First Approval Expected in 1H 2025 Raises 2028 Revenue Outlook from $500 Million to $700 Million Representing a 29% CAGR Highly Capital Efficient Deal Structure Funded Through $50 Million Pharmakon Tranche; Company Expects to Rem...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023, after the U.S. financial mark...

2023-04-19 06:28:30 ET Summary The US neurotoxin market is rapidly growing, and Evolus has a strong position in the market, especially among younger, aesthetically-oriented consumers. The global market for non-invasive aesthetic treatments is expected to reach $150 billion by 2030...

2023-03-08 21:36:02 ET Evolus, Inc. (EOLS) Q4 2022 Earnings Conference Call March 08, 2023 04:30 PM ET Company Participants David Erickson - Vice President of Investor Relations David Moatazedi - President and Chief Executive Officer Rui Avelar - Chief Medical Of...

2023-03-08 16:12:35 ET Evolus press release ( NASDAQ: EOLS ): Q4 GAAP EPS of -$0.23 misses by $0.02 . Revenue of $43.65M (+25.9% Y/Y) misses by $0.17M . Outlook: Evolus continues to expect total net revenues for full year 2023 to be between $180 million and...

Q4 2022 Net Revenue Reached an All-Time High of $43.6 Million, Up 26% from Q4 2021 Full-Year 2022 Net Revenue of $148.6 Million, Up 49% Over 2021 Reaffirms Full-Year 2023 Net Revenue Guidance of $180 to $190 Million and Positive Non-GAAP Operating Income 1 in Q4 2023 ...